Filing Flows

Filing Flows › Jazz Pharmaceuticals (JAZZ) › Next earnings date

Jazz Pharmaceuticals (JAZZ) earnings: missed the estimate

Jazz Pharmaceuticals (JAZZ) reported on Nov 2, 2026 and missed the EPS estimate: −$3.88 against −$2.38 (-63.4%). Revenue was $1.2B for Q3 2026, +10% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−63.4% vs estimate
Beat rate60%

The last report

Jazz Pharmaceuticals reported revenue of $1.2B for the third quarter 2026 (+10% Y/Y), net loss $483M: Sleep $514M, Xywav $482M, Rylaze/Enrylaze $106M, Zepzelca $104M. How it makes money → · Every quarter →

Jazz Pharmaceuticals: EPS against the estimate, last 5 reportsJazz Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$5.85$8.13Nov 25$2.89$3.21Feb 26$4.66$6.34May 26$6.18$5.71Aug 26−$2.38−$3.88Nov 26
Latest (Nov 26): Estimate −$2.38, Reported −$3.88.

Jazz Pharmaceuticals' latest quarter

Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.

Questions

Did Jazz Pharmaceuticals beat earnings?

Jazz Pharmaceuticals (JAZZ) reported on Nov 2, 2026 and missed the EPS estimate: −$3.88 against −$2.38 (-63.4%).

When does JAZZ report earnings?

The next date is not set yet.

Does Jazz Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.